{
    "clinical_study": {
        "@rank": "18503", 
        "arm_group": {
            "arm_group_label": "paclitaxel liposome injection plus cisplatin", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pathological complete response (pCR) rate in\n      breast cancer patients treated with weekly paclitaxel liposome injection plus cisplatin\n      preoperative regimen."
        }, 
        "brief_title": "Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged \u2265 18 years and < 65 years,An estimated life expectancy of at least 12\n             months\n\n          -  ECOG 0-1\n\n          -  At least one measurable disease according to the RECIST. histologically confirmed\n             invasive breast cancer, stage II and III, no prior systemic or loco-regional\n             treatment of breast cancer\n\n          -  Biopsy specimens are available for ER, PgR and Her2 analysis\n\n          -  Adequate bone marrow function: Neutrophil \u2265 1.5*109/L; Hb \u2265 100g/L; PLT \u2265 100*109/L\n\n          -  adequate liver function (bilirubin > 1.0 times upper normal limit [UNL] and ALT\n             and/or AST> 1.5 UNL associated with alkaline phosphatase > 2.5 UNL;\n\n          -  Women with potential child-bearing must have a negative pregnancy test (urine or\n             serum) within 7 days of drug administration and agree to use an acceptable method of\n             birth control to avoid pregnancy for the duration of the study\n\n          -  No obvious main organs dysfunction\n\n          -  patients must be accessible for treatment and follow-up and written informed consent\n\n        Exclusion Criteria:\n\n          -  Patient is pregnant or breast feeding\n\n          -  Inflammatory breast cancer and Metastatic breast cancer\n\n          -  Patients with medical conditions that indicate intolerant to neoadjuvant therapy and\n             related treatment, including uncontrolled pulmonary disease, diabetes mellitis,\n             severe infection, active peptic ulcer, coagulation disorder, connective tissue\n             disease or myelo-suppressive disease\n\n          -  History of congestive heart failure, uncontrolled or symptomatic angina pectoris,\n             arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP >\n             180 mmHg or diastolic BP > 100 mmHg)\n\n          -  Has peripheral neuropathy\n\n          -  Treatment with any investigational drugs within 30 days before the beginning of study\n             treatment\n\n          -  No psychiatric illness and other situations that would limit compliance of study\n\n          -  With a history of other malignant tumor\n\n          -  Known severe hypersensitivity to any drugs in this study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142010", 
            "org_study_id": "LY-TM-LPS-2014-01"
        }, 
        "intervention": {
            "arm_group_label": "paclitaxel liposome injection plus cisplatin", 
            "description": "Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2,  given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)", 
            "intervention_name": "paclitaxel liposome injection plus cisplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "lujjss@126.com", 
                "last_name": "Jinsong Lu, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "Shanghai Jiaotong University School of Medicine, Renji Hospital"
            }, 
            "investigator": {
                "last_name": "Jinsong Lu, Phd", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "lujjss@126.com", 
            "last_name": "Jinsong Lu, MD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pathological complete remission (pCR) rate", 
            "safety_issue": "No", 
            "time_frame": "after 4 months of preoperative treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142010"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "4 months during neoadjuvant therapy"
            }, 
            {
                "measure": "clinical response rate", 
                "safety_issue": "No", 
                "time_frame": "after 4 months of preoperative therapy"
            }
        ], 
        "source": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}